Ipsen Provides an Update on 2020 Strategy and Outlook at Investor Day
Business Wire - Thu Jul 02, 12:00AM CDT
--Sales growth acceleration with a 2020 outlook for organic sales of EUR1.8bn to EUR2bn and a core operating margin(1) of above 26%
Roche On The Wrong Side For Once In Shifting Analyst Forecasts
EP Vantage - Seeking Alpha - Sat Jun 06, 7:32AM CDT
Roche 's ( OTCPK:RHHBF ) ( OTCQX:RHHBY ) reputation as a peerless R&D powerhouse has taken a battering in the past year, and as a consequence, two of its abandoned projects have made the list of top downgrades of the past 12 months. On the...
SGYP: 9.13 (+0.49), VRTX: 122.95 (+2.06), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), IBB: 372.80 (+6.06), PBYI: 106.25 (-2.12), NVS: 103.22 (+3.20)
Ipsen initiates a share buyback program
Business Wire - Tue Jun 02, 11:59PM CDT
Regulatory News:
Ipsen confirms its eligibility for PEA-PME
Business Wire - Mon Jun 01, 11:59PM CDT
Regulatory News:
Combined Shareholders' Meeting of IPSEN S.A. held on 27 May 2015
Business Wire - Thu May 28, 11:59PM CDT
Regulatory News:
Ipsen buys German radiopharmaceuticals maker
Seeking Alpha - at Seeking Alpha - Wed May 27, 3:31PM CDT
Ipsen Strengthens Its Presence in the Oncology Field with the Acquisition of OctreoPharm Sciences, a Company Developing Innovative Radiopharmaceuticals for the Diagnosis and Treatment of Neuroendocrine Tumours
Business Wire - Tue May 19, 11:07AM CDT
--Upfront and downstream payments reaching EUR50 million
Ipsen Announces Data Presentations for Somatuline(R) Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
Business Wire - Thu May 14, 8:17AM CDT
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext:IPN; ADR:IPSEY), today announced that abstracts of data regarding Somatuline(R) Depot (lanreotide) Injection 120 mg (referred to as Somatuline(R)) will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, May 29 - June 2, 2015. The data include a poster discussion of a new subgroup analysis of the Phase III CLARINET(R) study in patients with midgut neuroendocrine tumors (NETs).
Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year
Business Wire - Wed Apr 29, 12:00AM CDT
--Specialty care sales up 14.6%(1)
Active Bio and Ipsen call it quits in prostate cancer
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 7:42AM CDT
Active Biotech and Ipsen Announce Their Decision to Discontinue the Development of tasquinimod in Prostate Cancer
Business Wire - Thu Apr 16, 12:00AM CDT
Regulatory News:
Ipsen Biopharmaceuticals expands to Canada
CNW Group - Wed Apr 15, 7:45AM CDT
International pharmaceutical company opens new headquarters in Ontario
Ipsen and Hannover Medical School Start Joint Research in Recombinant Botulinum Neurotoxins for Targeted Secretion Inhibitors
Business Wire - Wed Apr 08, 1:00AM CDT
Regulatory News:
Ipsen Expands Ties to Harvard University with Signing of a New Research Alliance Agreement
Business Wire - Wed Apr 01, 11:00AM CDT
Regulatory News:
Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence
Business Wire - Wed Apr 01, 6:00AM CDT
Regulatory News:
Ipsen's 2014 Results and 2015 Financial Objectives
Business Wire - Tue Mar 03, 12:00AM CST
--Core diluted EPS of EUR2.22, up 20.3%
Ipsen Announces Third Resupply of Increlex(R) (mecasermin [rDNA origin] Injection) in the U.S. in 2015
Business Wire - Mon Mar 02, 11:00AM CST
--Ipsen continues to work with the FDA to release future batches of Increlex(R)
Dominique Laymand is Appointed as Ipsen's Senior Vice President, Chief Ethics and Compliance Officer
Business Wire - Mon Mar 02, 3:00AM CST
Regulatory News:
DBV Technologies Welcomes Dr. J-P Moreau to its Scientific Advisory Board
GlobeNewswire - Fri Feb 13, 12:46AM CST
DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, announced today the appointment of Dr Jacques-Pierre Moreau to its Scientific Advisory Board. Dr. Moreau brings to DBV his unique expertise and knowledge across a wide range of disease areas and will contribute in defining aggressive approaches to potentially extend the use of epicutaneous immunotherapy (EPIT(R)) and Viaskin(R) technology to a wide range of therapeutic opportunities.
RDUS: 72.61 (+2.58), DBVT: 35.36 (+3.04)
Ipsen: Sales in the Fourth Quarter and Full Year 2014
Business Wire - Tue Feb 03, 1:30AM CST
--Specialty care sales up 9.9%(1) in 2014